Evidence map›Paper›PMID 39913081›Full record

ArticleCardiovascular drugs and therapy2026

The Combined Empagliflozin and Sacubitril/Valsartan Therapy Attenuates Isoproterenol-Induced Heart Failure in Rats: Functional, Molecular, and Structural Insights.

Maja Muric, Ivan Srejovic, Jovana Novakovic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Marina Nikolic, Nevena Lazarevic, Marijana Andjic, Aleksandar Kocovic and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Plants (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maja MuricDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Ivan SrejovicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia. ivan_srejovic@hotmail.com.ORCID 0000-0002-3835-1856
Jovana NovakovicCenter of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Vladimir ZivkovicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jovana Joksimovic JovicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jasmina SretenovicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Marina NikolicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Nevena LazarevicCenter of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Marijana AndjicCenter of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Aleksandar KocovicCenter of Excellence for the Study of Redox Balance in Cardiovascular and Metabolic Disorders, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.
Jovana Jakovljevic UzelacInstitute of Medical Physiology "Richard Burian", Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
Sergey BolevichDepartment of Human Pathology, 1St Moscow State Medical University IM Sechenov, Moscow, Russia.
Vladimir JakovljevicDepartment of Physiology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia.

Funding

Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu JP 01/24Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja No. 451-03-65/2024-03/200111
6 · The paper itself

Abstract

purposeThe idea behind this study was to assess the effects of empagliflozin and sacubitril/valsartan and their combination on isoproterenol-induced heart failure (HF) and underlying molecular mechanisms.

methodsHF was induced with 7-day isoproterenol (5 mg/kg daily), confirmed by ejection fraction below 55% after 4 weeks. HF rats received empagliflozin, sacubitril/valsartan, or both for 4 weeks. Parameters measured included hemodynamics, cardiac function, redox status, and histomorphology.

resultsIsoproterenol impaired hemodynamics and cardiac function, increased oxidative damage, and altered cardiac structure. All treatments were cardioprotective; however, combined empagliflozin and sacubitril/valsartan therapy had the most pronounced effect.

conclusionCombined empagliflozin and sacubitril/valsartan showed superior cardioprotection in HF, primarily by enhancing antioxidative effects. These findings support early use of both drugs in HF treatment.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsAntioxidantsBenzhydryl CompoundsGlucosidesHeart FailureIsoproterenolSodium-Glucose Transporter 2 InhibitorsTetrazolesValsartanVentricular Function, LeftAnimalsBiphenyl CompoundsDisease Models, AnimalDrug CombinationsHemodynamicsAminobutyratesAngiotensin Receptor AntagonistsAntioxidantsBenzhydryl CompoundsBiphenyl CompoundsDrug CombinationsempagliflozinGlucosidesIsoproterenolsacubitril and valsartan sodium hydrate drug combinationSodium-Glucose Transporter 2 InhibitorsTetrazolesValsartanCardiac functionEmpagliflozinHeart failureOxidative stressSacubitril/valsartan

Identifiers

PMID39913081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.